Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 6/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22962263 | 0.85 | KDM4E (0.42) | ALDH1A1POLBCDK9DYRK1ANQO2 | |
| SCHEMBL6958259 | 0.83 | KEAP1 (0.42) | ALDH1A1POLBCDK9DYRK1ANQO2 | |
| SCHEMBL6935072 | 0.78 | NQO2 (0.44) | ALDH1A1POLBCDK9DYRK1ANQO2 | |
| SCHEMBL4611131 | 0.76 | ALDH1A1 (0.46) | ALDH1A1POLBCDK9DYRK1ANQO2 | |
| SCHEMBL4420447 | 0.76 | NQO2 (0.46) | ALDH1A1POLBCDK9DYRK1ANQO2 | |
| SCHEMBL23676489 | 0.76 | CYP3A4 (0.41) | CDK9DYRK1ANQO2MAPTMEN1 | |
| SCHEMBL941422 | 0.75 | KEAP1 (0.47) | ALDH1A1POLBCDK9DYRK1ANQO2 | |
| SCHEMBL31723877 | 0.75 | DCPS (0.47) | ALDH1A1POLBCDK9DYRK1ANQO2 | |
| SCHEMBL24834182 | 0.75 | DCPS (0.47) | ALDH1A1POLBCDK9DYRK1ANQO2 | |
| SCHEMBL2549634 | 0.75 | NQO2 (0.44) | ALDH1A1POLBCDK9DYRK1ANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1741714-B1 | HETEROCYCLIC COMPOUND AND ANTI-MALIGNANT-TUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-8338414-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-1864665-B1 | IMMUNOSUPPRESSIVE AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2012-05-16 | — | — | EP | disclosed |
| EP-2411387-A2 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7855199-B2 | antitumor agents such as 2-(2-difluoromethyl-4-methoxybenzimidazol-1 -yl)-4-(cis-2,6-dimethylmorpholino)-6-morpholinopyrimidine, used for inhibiting the growth of a human colon cancer cell, a human lung cancer cell, a human breast cancer cell or a human prostate cancer cell | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100267700-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-10-21 | — | — | US | disclosed |
| WO-2010110685-A2 | PYRIMDDINYL AND 1,3,5-TRIAZINYL BENZIMTOAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| US-7750001-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20080287431-A1 | Heterocyclic Compound and Anti-Malignant-Tumor Agent Containing the Same as Active Ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1864665-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1741714-A1 | HETEROCYCLIC COMPOUND AND ANTI-MALIGNANT-TUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267700-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | ALDH1A1 2283/4885POLB 4437/4885CDK9 2682/4885 |
| US-20080287431-A1 | Heterocyclic Compound and Anti-Malignant-Tumor Agent Containing the Same as Active Ingredient | TP53, RB1, VHL | ALDH1A1 2121/4885POLB 2206/4885CDK9 645/4885 |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | ALDH1A1 2283/4885POLB 4437/4885CDK9 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.